March 2020

Column

Editor's Page

Real-World Data Analysis and Considerations for Use

03/16/2020

Google the question “what is real-world evidence.” One of the first citations will be a link to the Food and Drug Administration (FDA) page defining both real-world evidence (RWE) and real-world data (RWD). The FDA...

Google...

03/16/2020

Journal of Clinical Pathways

Trending From ACCC

Financial Advocacy Network: Hub for Education, Resources, and Peer-to-Peer Learning

03/16/2020

JCP Editors

Over the past decade, the field of oncology has seen remarkable advances stemming from a better understanding of the molecular biology of many cancer types. This growing body of knowledge has led to improvements in...

Over...

03/16/2020

Journal of Clinical Pathways

Pharma Insights

Where Incentives Align (or Don’t) Among Health Care Stakeholders and How They Are Evolving

03/16/2020

Jeremy Schafer , PharmD, MBA;

Avi Mamidi , PharmD;

Larry Blandford , PharmD;

Elizabeth Oyekan , PharmD, FCSHP, CPHQ;

The goal of all health care stakeholders—payers, providers, and health systems—is to lower health care costs and improve patient health outcomes, yet the path to getting to this goal remains questionable, partially...

The...

03/16/2020

Journal of Clinical Pathways

Engaging Payers

Building Episodes of Care Models for Oncology & Other Chronic Conditions

03/16/2020

Lili Brillstein , MPH;

The episodes of care payment model is designed to put the patient at the center of care delivery, with their care coordinated among all providers for more comprehensive care to achieve the best possible outcomes....

The...

03/16/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease

03/16/2020

Matthew Pakizegee , PharmD, MS;

Jonathan W. Hodgson , MBA;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Chad McAuliffe ;

Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...

...

03/16/2020

Journal of Clinical Pathways

Insights

Interview

Real-World Analysis Potential Impact on Standard Management of Tumor Lysis Syndrome in Adults With Leukemia, Lymphoma

03/16/2020

JCP Editors

An interview with Scott C Howard, MD, MSc, University of Tennessee Health Sciences Center, Memphis TN. Many health professionals are talking about the use of real-world data and evidence to advance medical...

An...

03/16/2020

Journal of Clinical Pathways

Column

Making the Switch to Biosimilars With Clinical Pathways

03/16/2020

Gary H. Lyman , MD, MPH, FASCO, FRCP, FACP;

This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...

This...

03/16/2020

Journal of Clinical Pathways

Column

Navigating the Complexities of Novel Treatment Sequencing for AML

03/16/2020

Daniel A. Pollyea , MD, MS;

This...

03/16/2020

Journal of Clinical Pathways

Feature

Research Reports

Real-World Analysis of Outpatient Rasburicase to Prevent and Manage Tumor Lysis Syndrome in Newly Diagnosed Adults With Leukemia or Lymphoma

03/16/2020

Alex R. Cockerham , PharmD, RPh, MSc;

William Irish , PhD;

Edward Drea , PharmD;

Michael P. Ryan , MS;

Lucio Gordan , MD;

Yvonne Barnes , DNP, RN;

Scott C. Howard , MD, MSc;

Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...

...

03/16/2020

Journal of Clinical Pathways

Perspectives

The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study

03/16/2020

Ray Page , DO, PhD, FACOI, FASCO;

Andrew Hertler , MD, FACP;

Steve L. D'Amato , BSPharm, BCOP;

Michael Kolodziej , MD;

Barry Brooks , MD;

William A. Flood , MD, MS;

Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...

...

03/16/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

March 2020

Column

Insights

Feature

Current Issue

Special Reports

Subscribe

Volume 6

Specialties

Events

Year Round Education

HMP Global Products